For decades we have been learning about the interplay between tumors and the immune system. Our knowledge seemed somewhat incomplete and indirect, like listening to the ocean waves through a shell. Only recently, cancer immunotherapy has started to become a reality, with Provenge (Dendreon Corporation, WA), an autologous antigen-presenting cell preparation, earning the approval of United States Food and Drug Administration (FDA) for the treatment of advanced prostate cancer in 2010. This book provides an excellent review of the field of cancer immunotherapy, with special focus on prostate cancer, one of the most common cancers and a leading cause of.
